Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Blood (2024) 144 (Supplement 1): 990.

https://doi.org/10.1182/blood-2024-200096

Published: 2024

Journal Articles

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Blood (2024) 144 (Supplement 1): 644.

https://doi.org/10.1182/blood-2024-201406

Published: 2024

Journal Articles

Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients

Candice Jamois, Koorosh Korfi, Sylvia Herter, Sabine Wilson, Sreenath Krishnan, Marie-Helene Wasmer, Isabel Prieto, Heather Hinton, Wouter Driessen, Georgios Kazantzidis, Denis Sahin, Akiko Tagawa, Natalie Dimier, Katharina Lechner

Blood (2024) 144 (Supplement 1): 4180.

https://doi.org/10.1182/blood-2024-201466

Published: 2024

Journal Articles

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

Blood (2024) 144 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2024-205544

Published: 2024

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Blood (2023) 142 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2023-173677

Published: 2023

Journal Articles

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2022) 140 (Supplement 1): 9461–9463.

https://doi.org/10.1182/blood-2022-157011

Published: 2022

Journal Articles

Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-136571

Published: 2020

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Ann-Marie E Bröske, PhD, Ian James, PhD, Anton Belousov, PhD, Enrique Gomez, PhD, Marta Canamero, MD PhD, Chia-Huey Ooi, PhD, Nils Grabole, PhD, Sabine Wilson, PhD, Koorosh Korfi, PhD, Nicole A Kratochwil, PhD, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Denise Thomas, MSc, Natalie Dimier, PhD, Tom Moore, MBChB, Marina Bacac, PhD, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 5319.

https://doi.org/10.1182/blood-2019-123979

Published: 2019

Journal Articles

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Chi-Chung Li, PhD, Brendan Bender, PhD, Shen Yin, PhD, Zao Li, PhD, Cindy Zhang, MS, Genevive Hernandez, PhD, Antonia Kwan, MD PhD MRCPCH, Laura Sun, PhD, Joanne I Adamkewicz, PhD, Hong Wang, MD PhD DABT, Natalie Dimier, PhD, Sue-Zen Lim, BPharm, Carol O'Hear, MD PhD, Laurie H Sehn, MD, Ian W. Flinn, MD PhD, Sung-Soo Yoon, MD PhD, Lihua E Budde, MD PhD, Chunze Li, PhD, Michael C Wei, MD PhD

Blood (2019) 134 (Supplement_1): 1285.

https://doi.org/10.1182/blood-2019-123961

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nassim Djebli, PhD PharmD, Felix Jaminion, MSc, Johann Laurent, MSc, Francois Mercier, PhD, Nicole A Kratochwil, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Tom Moore, MBChB, Martin Weisser, MD, Peter N Morcos, PharmD

Blood (2019) 134 (Supplement_1): 3799.

https://doi.org/10.1182/blood-2019-123712

Published: 2019

Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 1584.

https://doi.org/10.1182/blood-2019-123949

Published: 2019

Journal Articles

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Franck Morschhauser, MD, Fritz Offner, MD, Anna Sureda, MD, Gilles Andre Salles, MD PhD, Carmelo Carlo-Stella, MD, Joaquin Martinez Lopez, MD, Denise Thomas, BS, Peter N Morcos, PhD, Betsy Quackenbush, MD, Cristiano Ferlini, MD, Marina Bacac, PhD, Ann-Marie E. Broeske, PhD, Natalie Dimier, PhD, Tom Moore, MD, Martin Weisser, MD, Michael Dickinson, MD

Blood (2018) 132 (Supplement 1): 226.

https://doi.org/10.1182/blood-2018-99-110207

Published: 2018

Journal Articles

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba, Michael Hallek

Blood (2018) 131 (9): 955–962.

https://doi.org/10.1182/blood-2017-06-792333

Published: 2018

Includes: Supplemental data

Journal Articles

Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

Stephen Couban, MDBSc, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, MD PhD, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Ian Templeton, Francesco Passamonti

Blood (2017) 130 (Supplement 1): 4179.

https://doi.org/10.1182/blood.V130.Suppl_1.4179.4179

Published: 2017

Journal Articles

A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia

Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Gunter Fingerle-Rowson, Jasmin Bahlo, Kirsten Fischer, MD, Barbara F. Eichhorst, MD, Valentin Goede, MD, Jacques J.M. van Dongen, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Anton W. Langerak, Michael Kneba, Michael Hallek, MD

Blood (2015) 126 (23): 720.

https://doi.org/10.1182/blood.V126.23.720.720

Published: 2015

Journal Articles

Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

Bruce D. Cheson, MD, Peter C Trask, PhD MPH, John Gribben, MDDSc, Natalie Dimier, Eva Kimby, MD PhD, Pieternella J Lugtenburg, MD PhD, Catherine Thieblemont, Elisabeth Wassner Fritsch, MD, Laurie H Sehn, MD MPH

Blood (2015) 126 (23): 1532.

https://doi.org/10.1182/blood.V126.23.1532.1532

Published: 2015

NARROW

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia

Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only